Passage Bio (PASG) Expected to Announce Earnings on Tuesday

Passage Bio (NASDAQ:PASG) is expected to be announcing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($2.79) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Passage Bio (NASDAQ:PASG) last issued its earnings results on Tuesday, March 3rd. The company reported ($4.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.19) by ($1.89). On average, analysts expect Passage Bio to post $-8 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

Passage Bio Stock Down 3.6%

Shares of NASDAQ PASG traded down $0.16 during midday trading on Tuesday, hitting $4.41. The stock had a trading volume of 60,895 shares, compared to its average volume of 75,790. The business’s 50 day moving average is $8.04 and its 200-day moving average is $9.40. The company has a market cap of $14.13 million, a P/E ratio of -0.30 and a beta of 1.38. Passage Bio has a 52 week low of $4.26 and a 52 week high of $20.00.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Quadrature Capital Ltd purchased a new stake in Passage Bio during the fourth quarter valued at approximately $148,000. Squarepoint Ops LLC purchased a new stake in Passage Bio during the third quarter valued at approximately $188,000. Geode Capital Management LLC increased its holdings in Passage Bio by 15.1% during the fourth quarter. Geode Capital Management LLC now owns 31,397 shares of the company’s stock valued at $371,000 after buying an additional 4,114 shares during the last quarter. Yiheng Capital Management L.P. purchased a new stake in Passage Bio during the fourth quarter valued at approximately $405,000. Finally, Renaissance Technologies LLC increased its holdings in Passage Bio by 8.2% during the fourth quarter. Renaissance Technologies LLC now owns 109,089 shares of the company’s stock valued at $1,287,000 after buying an additional 8,300 shares during the last quarter. 53.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on PASG shares. Wall Street Zen upgraded shares of Passage Bio from a “strong sell” rating to a “sell” rating in a research note on Sunday. TD Cowen downgraded shares of Passage Bio from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Oppenheimer dropped their target price on shares of Passage Bio from $30.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, April 21st. Wedbush reissued a “neutral” rating and set a $8.00 price objective (down from $32.00) on shares of Passage Bio in a report on Tuesday, April 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Passage Bio in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $13.25.

About Passage Bio

Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.

The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit.